Issues

The cover image is adapted from Figure 1 in the article “The Movember Global Action Plan 1 (GAP1) - Unique Prostate Cancer Tissue Microarray Resource,” by Ouellet and colleagues. The original figure shows the representative low power view of staining of TMA cores from test-TMA 1 (Primary Matched LN). The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project constructed a set of unique and richly annotated TMAs from prostate cancer samples obtained from multiple institutions across several global locations. This robust resource could not have been assembled using samples from any single institution. The GAP1-UTMA project has succeeded in combining a large set of tissue specimens from 501 prostate cancer patients with rich clinical annotation. This resource is now available to the prostate cancer community as a tool for biomarker validation to address important unanswered clinical questions around disease progression and response to treatment. For more information, see the article beginning on page 715.